INOVIO PHARMACEUTICALS, INC. Cash Flow Statement
INO|15 years of annual SEC 10-K data (FY2011-FY2025)
Covers operating cash flow, capital expenditures, free cash flow, share buybacks, and dividends paid across 15 fiscal years. All figures from audited SEC 10-K filings.
INOVIO PHARMACEUTICALS, INC. used $104M in operating cash flow and negative free cash flow of $105M in FY2025.
Based on SEC 10-K filings.
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score 0.43 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
| Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | FY2015 | FY2014 | FY2013 | FY2012 | FY2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Income | -$107.3M | -$135.1M | -$303.7M | -$166.4M | -$119.4M | -$97.0M | -$88.2M | -$73.7M | -$29.2M | -$36.1M | -$66.0M | -$19.7M | -$15.3M | -$17.6M | -$24.4M |
| Depreciation & Amortization | $1.8M | $2.6M | $3.0M | $3.0M | $3.6M | $3.7M | $1.9M | $1.7M | $1.0M | $626.6K | $328.8K | $173.8K | $142.2K | $194.6K | $237.2K |
| Operating Cash Flow | -$104.1M | -$124.4M | -$215.7M | -$178.0M | -$97.9M | -$73.6M | -$63.2M | -$62.6M | -$12.4M | -$29.8M | -$15.4M | -$22.3M | -$19.8M | -$11.9M | -$14.1M |
| Capital Expenditures | $487.8K | $320.9K | $1.2M | $1.5M | $987.9K | $2.1M | $10.3M | $2.7M | $2.8M | $1.4M | $176.9K | $241.0K | $161.2K | $181.6K | $48.4K |
| Free Cash Flow | -$104.6M | -$124.7M | -$216.9M | -$179.5M | -$98.8M | -$75.6M | -$73.5M | -$65.3M | -$15.2M | -$31.2M | -$15.6M | -$22.5M | -$19.9M | -$12.1M | -$14.1M |
| FCF Margin | -48019.1% | -14986.2% | -12223.6% | -2422.0% | -2403.7% | -248.1% | -174.1% | -184.6% | -37.5% | -298.4% | -115.5% | -547.5% | -203.3% | -197.2% | -154.9% |